Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16178692 | 0.98 | GABRA1 (0.52) | GABRA1GABRB2GABRG2GABRB3LMNA | |
| SCHEMBL1515432 | 0.83 | GABRA1 (0.40) | GABRA1GABRB2GABRG2GABRB3LMNA | |
| SCHEMBL27368536 | 0.79 | TSHR (0.57) | GABRA1GABRB2GABRG2GABRB3LMNA | |
| SCHEMBL14803938 | 0.79 | ALDH1A1 (0.35) | GABRA1GABRB2GABRG2GABRB3LMNA | |
| SCHEMBL10002398 | 0.78 | CXCL8 (0.42) | GABRA1GABRB2CYP1A2CYP3A4ALOX5 | |
| SCHEMBL30832479 | 0.77 | L3MBTL1 (0.34) | GABRA1GABRB2LMNASLC6A2CYP3A4 | |
| SCHEMBL29186875 | 0.77 | L3MBTL1 (0.34) | GABRA1GABRB2LMNASLC6A2CYP3A4 | |
| SCHEMBL269332 | 0.76 | GABRA1 (0.46) | GABRA1GABRB2GABRG2GABRB3LMNA | |
| SCHEMBL12090332 | 0.76 | GABRA1 (0.46) | GABRA1GABRB2GABRG2GABRB3LMNA | |
| SCHEMBL23790474 | 0.74 | GABRA1 (0.46) | GABRA1GABRB2GABRG2GABRB3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| WO-2014091265-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-06-19 | — | — | WO | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-11-13 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024038282-A1 | 2-AZA- AND 2-OXABICYCLO[2.1.1]HEXANE DERIVATIVES AS FACTOR XIIA ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11873290-B2 | — | — | 2024-01-16 | — | — | US | disclosed |
| US-11873290-B2 | — | — | 2024-01-16 | — | — | US | disclosed |
| WO-2023230542-A2 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-7879851-B2 | such as (E)-3-[2-(1-{[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carbonyl]-amino}-cyclobutyl)-3-methyl-3H-benzoimidazol-5-yl]-acrylic Acid, used for the treatment of hepatitis C virus infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20110015203-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-7582770-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20090170805-A1 | ANTI-MICROBIAL AGENTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
| US-20080293666-A1 | Antibacterial Agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-11-27 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | GABRA1 240/4885GABRB2 561/4885GABRG2 508/4885 |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | GABRA1 751/4885GABRB2 671/4885GABRG2 1241/4885 |
| US-11873290-B2 | — | IL6, MUSK, IL6ST | GABRA1 641/4885GABRB2 977/4885GABRG2 1363/4885 |
| US-20080293666-A1 | Antibacterial Agents | MRPL21, ABCB7, MSR1 | GABRA1 1965/4885GABRB2 1511/4885GABRG2 2888/4885 |
| US-20090170859-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | GABRA1 3007/4885GABRB2 2836/4885GABRG2 3936/4885 |
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GK, GCK | GABRA1 178/4885GABRB2 75/4885GABRG2 121/4885 |
| US-20110015203-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | GABRA1 3007/4885GABRB2 2836/4885GABRG2 3936/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | GABRA1 3911/4885GABRB2 4277/4885GABRG2 4247/4885 |
| US-20090170805-A1 | ANTI-MICROBIAL AGENTS AND USES THEREOF | ACAT1, ACAT2, APEH | GABRA1 3823/4885GABRB2 4243/4885GABRG2 4488/4885 |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | WRN, RECQL, BLM | GABRA1 4502/4885GABRB2 4136/4885GABRG2 4220/4885 |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | MALT1, FKBP1B, FKBP1A | GABRA1 1284/4885GABRB2 2464/4885GABRG2 1901/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | GABRA1 240/4885GABRB2 561/4885GABRG2 508/4885 |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | GABRA1 734/4885GABRB2 1304/4885GABRG2 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.